Shares of Black Diamond Therapeutics Inc. (BDTX) are up nearly 40% at $2.34 in premarket trading today, on news of the company entering into a strategic worldwide licensing agreement for its investigational drug BDTX-4933, with Servier, an independent global pharmaceutical group governed by a non-profit foundation.
BDTX-4933, designed to target RAS and RAF alterations in solid tumors, is currently in phase I development.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.